ruboxistaurin

Known as: 13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione, ruboxistaurin [Chemical/Ingredient] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
OBJECTIVE Factors released by perivascular adipose tissue (PVAT) disrupt coronary endothelial function via phosphorylation of… (More)
Is this relevant?
2009
2009
PURPOSE To compare relationships between severity and duration of diabetic macular edema (DME) and visual acuity (VA) observed in… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Protein kinase (PK)Calpha, PKCbeta, and PKCgamma comprise the conventional PKC isoform subfamily, which is thought to regulate… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2009
2009
BACKGROUND Heart failure is a common cause of morbidity and mortality in diabetic patients that frequently manifests in the… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2008
2008
Type-2 diabetes mellitus increases risk of atherosclerotic cardiovascular disease. However, the mechanisms linking hyperglycemia… (More)
  • figure 1
  • table 1
  • table 3
Is this relevant?
2007
2007
BACKGROUND A pilot study showed that ruboxistaurin (RBX), a protein kinase C beta inhibitor, significantly decreased albuminuria… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE To evaluate the safety and efficacy of orally administered ruboxistaurin (RBX) as a mesylate salt in patients with… (More)
Is this relevant?
Review
2006
Review
2006
The aim of this manuscript is to report the safety profile of patients treated with ruboxistaurin mesylate (RBX; LY333531), a… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE To assess ocular and systemic safety and pharmacodynamic effects of the oral PKC beta selective inhibitor ruboxistaurin… (More)
  • table 2
  • table 3
  • table 4
  • table 5
  • figure 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVE Ruboxistaurin selectively inhibits protein kinase C-beta and ameliorates kidney disease in animal models of diabetes… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?